|
|
Volumn 104, Issue 3, 2012, Pages 172-177
|
|
New data on aspirin and colorectal cancer brings calls for new guidelines, more research.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTINEOPLASTIC AGENT;
TUMOR MARKER;
BLOOD;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL (TOPIC);
COLORECTAL TUMOR;
EVIDENCE BASED MEDICINE;
GASTROINTESTINAL HEMORRHAGE;
HEREDITARY NONPOLYPOSIS COLORECTAL CANCER;
HUMAN;
NOTE;
PRACTICE GUIDELINE;
RISK ASSESSMENT;
ANTICARCINOGENIC AGENTS;
ASPIRIN;
CLINICAL TRIALS AS TOPIC;
COLORECTAL NEOPLASMS;
COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS;
EVIDENCE-BASED MEDICINE;
GASTROINTESTINAL HEMORRHAGE;
HUMANS;
PRACTICE GUIDELINES AS TOPIC;
RISK ASSESSMENT;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 84858766331
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djs019 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
